European Psychiatry

Pathophysiology of thought disorder in schizophrenia
pp. 133s-133s(1)
Authors: McGuire P.K.; Quested D.; Spence S.; Murray R.; Frith C.; Liddle P.

MEG-based evidence of accelerated auditory processing in schizophrenia
pp. 133s-133s(1)
Authors: Pekkonen E.; Huotilainen M.; Katila H.; Karhu J.; Naatanen R.; Tiihonen J.

Is cortical responsivity increased in schizophrenics predisposed to hallucinations?
pp. 133s-134s(2)
Authors: Woodruff P.W.R.; Blackwood N.; Ha Y.; Wright I.C.; Bullmore E.T.; Brammer M.; Howard R.J.; Williams S.C.R.; Shapleske J.; Rossell S.; Murray R.M.

What can functional imaging tell us about the aetiology of schizophrenia?
pp. 134s-134s(1)
Authors: Murray R.M.; Bullmore E.

Disablement and mental illness
pp. 134s-134s(1)
Author: Pull C.

The development of the WHO-DAS II
pp. 134s-134s(1)
Author: Chatterji S.

The field trials of the WHO-DAS II
pp. 134s-134s(1)
Author: Rehm J.

Results of the WHO-DAS II tests in the UK
pp. 134s-134s(1)
Author: Glozier N.

The EU initiative on assessment of disablement related to mental disorders
pp. 134s-134s(1)
Author: Mavreas V.

The assessment of disablement: the road ahead
pp. 135s-135s(1)
Author: Ustun T.B.

Medical education in alcoholism: the French experience
pp. 135s-135s(1)
Authors: Ades J.; Lejoyeux M.

Training of addiction specialists in Italy
pp. 135s-135s(1)
Authors: Poldrugo F.; Janiri L.

Education about addiction in Spanish Universities
pp. 135s-135s(1)
Author: Sanchez-Turet M.

A 2 weeks full-time mandatory course in addiction medicine integrated in the internal medicine-surgery curriculum. Experiences from the Malmoe model
pp. 136s-136s(1)
Author: Berglund M.

Education about addiction in the Netherlands
pp. 136s-136s(1)
Author: Hoes M.J.A.J.M.

Education about addiction in Germany
pp. 136s-136s(1)
Author: Boning J.

Depression in older persons: economic evaluation of a clinical trial of sertraline
pp. 136s-137s(2)
Author: Stewart A.

A health policy analysis of pharmacotherapy for major depressive disorder in Europe and the Americas
pp. 137s-137s(1)
Authors: Arikian S.R.; Einarson T.R.; Casciano J.P.; Doyle J.J.

Exploration of the use of the contingent valuation method to determine public preferences and valuations for the benefits of anti-depressant prescribing policies
pp. 137s-137s(1)
Authors: Healey A.; Chisholm D.; Weich S.

Variation in GP prescribing for patients with depression
pp. 137s-137s(1)
Author: Almond S.

The costs of comorbidity; anxiety and depression
pp. 137s-137s(1)
Authors: Kavanagh S.; Knapp M.

Gender differences and mental health
pp. 137s-138s(2)
Author: Petersson B.

With bated breath: cognitive and emotive aspects of breathing in patients with moderate asthma
pp. 138s-138s(1)
Author: Mirdal G.M.

Postpartum psychoses: clinical diagnoses and relative risk of admission
pp. 138s-138s(1)
Authors: Terp I.M.; Mortensen P.B.

Postpartum psychoses: prognosis and risk factors for readmission
pp. 138s-138s(1)
Authors: Terp I.M.; Engholm G.; Moller H.; Mortensen P.B.

Suffering of the body and mind: predictors for psychosomatic problems in female refugees
pp. 138s-138s(1)
Author: Arcel L.T.

Women's mental health in Ukraine
pp. 138s-139s(2)
Author: Bitenskaya V.

Harmonisation of psychiatric training in Greece before the dawn of the new millennium
pp. 139s-139s(1)
Authors: Kollias K.; Christodoulou G.N.

Current issues in psychiatric training in the UK
pp. 139s-139s(1)
Author: Cornwall P.L.

Psychiatric specialist training -- real or formal competence ahead?
pp. 139s-140s(2)
Author: Kaltiala-Heino R.

Residency training of psychiatrists in French speaking countries
pp. 140s-140s(1)
Author: Cloos J.M.

Striving for the harmonization of training in Europe: the work of the European board of psychiatry
pp. 140s-140s(1)
Author: Gomez-Beneyto M.

Neurasthenia and chronic fatigue syndrome: cross-cultural and conceptual issues
pp. 140s-140s(1)
Author: Starcevic V.

Epidemiology of neurasthenia
pp. 140s-141s(2)
Author: Angst J.

Diagnosis, assessment and management of chronic fatigue syndrome
pp. 141s-141s(1)
Author: Wessely S.

Chronic fatigue syndrome, serotonin and depression: how strong the link?
pp. 141s-141s(1)
Author: Cleare A.J.

A cognitive behaviour formulation and treatment of chronic fatigue syndrome
pp. 141s-142s(2)
Author: Sharpe M.

Effects of adequate lithium prophylaxis on suicidality and mortality of patients with affective disorders: retrospective and prospective studies
pp. 142s-142s(1)
Authors: Muller-Oerlinghausen B.; Ahrens B.

Who programme on the prevention of suicide: a global information network for monitoring suicide trends
pp. 142s-142s(1)
Author: Bertolote J.M.

Are there biological predictors of suicide?
pp. 142s-142s(1)
Authors: Traskman-Bendz L.; Engstrom G.; Eriksson H.; Lindstrom M.; Westrin A.

The fall downs of the WHO/EURO multicentre study on parasuicide
pp. 142s-143s(2)
Authors: Schmidtke A.; De Leo D.; Bille-Brahe U.; Crepet P.; Hjemeland H.; Kerkhof A.; Michel K.; Querejeta I.; Temesvary B.; Salander-Renberg E.; Sampaio-Faria J.; Wasserman D.

Suicide prevention -- an issue for the world bank
pp. 143s-143s(1)
Author: Jenkins R.

Identifying and treating depression in older adults: a key issue in suicide prevention
pp. 143s-143s(1)
Authors: De Leo D.; Scocco P.

Early antecedents of functional psychoses
pp. 143s-143s(1)
Authors: Jones P.; Isohanni M.; van Os J.

The early course of schizophrenia from onset until first admission
pp. 143s-143s(1)
Authors: Hafner H.; Maurer K.

Diagnosing schizophrenia in the prodromal phase
pp. 144s-144s(1)
Authors: Klosterkotter J.; Schultze-Lutter F.

Early intervention and the course of recent onset schizophrenia
pp. 144s-144s(1)
Authors: Linszen D.; Dingemans P.; Lenior M.; de Haan L.; Scholte P.

Early detection and treatment of affective disorder
pp. 144s-144s(1)
Author: Aldenhoff J.B.

The epidemiology and differential diagnosis of negative symptoms in schizophrenia
pp. 144s-145s(2)
Author: Lecrubier Y.

Negative symptoms: concepts and pathophysiology
pp. 145s-145s(1)
Author: Liddle P.

The measurement of negative symptoms
pp. 145s-145s(1)
Author: Dollfus S.

Treatment of negative symptoms in schizophrenia
pp. 145s-146s(2)
Author: Moller H.-J.

Are specific studies needed for negative symptoms in schizophrenia?
pp. 146s-146s(1)
Author: Fleischhacker W.W.

Application of 3D virtual reality (VR) -- systems in psychiatry
pp. 146s-146s(1)
Authors: Bullinger A.H.; Bergner J.; Roessler A.; Mueller-Spahn F.

The project of a national data bank for the psychiatric care in Italy
pp. 146s-146s(1)
Authors: Conti I.; Massimetti G.; Rossi A.; Bortone S.; Pancheri P.

Computers and structured diagnostic interviews in psychiatry
pp. 146s-147s(2)
Author: Pull C.B.

3D virtual reality (VR) systems, cognition and creativity
pp. 147s-147s(1)
Authors: Mueller-Spahn F.; Hofmann M.; Roessler A.; Bullinger A.H.

Italian psychiatry and computer aided integration between agencies and department facilities for improvement of patient management and quality control
pp. 147s-147s(1)
Authors: Furlan P.M.; Giammaria M.

Prediction of suicide in psychiatric patients by neural networks
pp. 147s-147s(1)
Authors: Modai I.; Greenstain S.; Solomish I.; Mendel S.

The occurrence of low birth weight, preterm birth, and perinatal death among children of schizo-phrenic women
pp. 148s-148s(1)
Authors: Bennedsen B.E.; Mortensen P.B.; Olesen A.V.

Early detection and intervention in first episode psychosis
pp. 148s-148s(1)
Authors: Haahr U.H.; Simonsen E.; Dahl A.; Olsen L.R.

Duration of psychosis before first admission
pp. 148s-148s(1)
Authors: Verdoux H.; Bergey C.; Assens F.; Abalan F.; Gonzales B.; Pauillac P.; Fournet O.; Liraud F.; Beaussier J.P.; Gaussares C.; Etchegaray B.; Bourgeois M.; van Os J.

The drug precription in schizophrenia: two complementary approaches
pp. 148s-149s(2)
Authors: Lachaux B.; Casadebaig F.; Philippe A.; Quemada N.; Ardiet G.; Guillaud-Bataille J.M.

Therapy of resistant psychoses: combined treatment with clozapine
pp. 149s-149s(1)
Authors: Lemmer W.; Agelink M.W.

Care pathways for psychosis & affective disorder
pp. 149s-149s(1)
Author: Kisely S.

Comparison of factor-analytical derived constructs of subjective quality of life in schizophrenic patients and healthy controls
pp. 149s-149s(1)
Authors: Meyer T.; Franz M.; Ehlers F.; Simon C.; Gallhofer B.

A model for multicentre collaboration in addiction research across Europe --experiences from ECCAS (European Collaborating Centres in Addiction Studies)
pp. 149s-150s(2)
Authors: Clancy C.; Oyefeso A.; Ghodse H.

The impact of MST (methadone substitution therapy) on HIV risk behaviour in opiate addicts
pp. 150s-150s(1)
Authors: Rosinger C.; Finkbeiner T.; Krings B.; Gastpar M.

Food and addiction
pp. 150s-150s(1)
Authors: Campana M.; Riglietta M.; Tidone L.

Benzodiazepines' consumption in a sample of methadone-maintained patients: characteristics of use and psychopathological profiles
pp. 150s-150s(1)
Authors: Forza G.; Levarta E.; Da Ros D.; Gentile N.; Schifano F.

Detoxification and rehabilitation of clients addicted to legally prescribed drugs
pp. 151s-151s(1)
Author: Sommer B.

Changes in recommendations for the treatment of panic disorder by an international panel of experts, 1992-1997
pp. 151s-151s(1)
Author: Uhlenhuth E.H.

Antidepressive treatment in suicidal patients
pp. 151s-151s(1)
Author: Muller-Oerlinghausen B.

Improving the diagnosis and treatment of depression: changes in morbidity, mortality and medication pattern
pp. 151s-151s(1)
Authors: Rutz W.; Walinder J.; Rihmer Z.

Psychopharmacoepidemiology in Iceland: the shift of prescriptions toward antidepressants
pp. 152s-152s(1)
Authors: Helgason T.; Zoega T.; Bjornsson J.K.; Tomasson H.

Who is treated, non treated and/or over treated in primary care?
pp. 152s-152s(1)
Authors: Lecrubier Y.; Paterniti S.; Hergueta T.

Reactive psychoses -- a valid diagnostic category after all
pp. 152s-152s(1)
Author: Dahl A.A.

Schizophrenia -- a changing concept?
pp. 153s-153s(1)
Author: Vaglum P.

The position of delusions in psychiatric nosography
pp. 153s-153s(1)
Author: Musalek M.

Dysphoria as a nosographical dis-organizer
pp. 153s-153s(1)
Author: Stanghellini G.

Neurosis -- an old concept which should be left behind?
pp. 153s-153s(1)
Author: Berner P.

Chronic pain -- changing concepts in psychiatry
pp. 153s-154s(2)
Authors: Barocka A.; Thurauf N.; Washeim H.A.

Pharmacotherapy in alcohol dependence: the need for consensus on the quality of clinical trials
pp. 154s-154s(1)
Authors: Drummond D.C.; Moncrieff J.

The Swedish naltrexone study, present results
pp. 154s-154s(1)
Authors: Balldin J.; Berglund M.; Borg S.; Mansson M.

Evaluation of the efficacy of acamprosate and psychotherapy
pp. 154s-154s(1)
Author: Soyka M.

Acamprosate, tiapride and psychotherapy in alcoholism: a post hoc comparison of matched patients from 3 prospective studies
pp. 154s-155s(2)
Authors: Mann K.F.; Ackermann K.; Bender S.; Gastpar M.; Sass H.

Methodology of the U.S. multicenter study of acamprosate in alcohol dependence
pp. 155s-155s(1)
Author: Mason B.J.

The epidemiology and comorbidity of eating disorders
pp. 155s-155s(1)
Authors: Flament M.F.; Godart N.; Vigan C.

Anorexia nervosa: individual and family assessment
pp. 155s-156s(2)
Author: Sampaio D.

Neurobiological findings in the eating disorders
pp. 156s-156s(1)
Author: Pirke K.M.

What's new in the treatment of bulimia nervosa?
pp. 156s-156s(1)
Author: Schmidt U.

The long-term outcome of eating disordered patients
pp. 156s-156s(1)
Author: Steinhausen H.-C.

Somatoform disorders in a medical department
pp. 156s-156s(1)
Authors: Oxhoj M.L.; Fink P.; Hansen M.S.; Eriksen M.

Somatization variants in disorders of depressive spectrum
pp. 157s-157s(1)
Author: Krasnov V.

Validity of different versions of the who-well-being scale for detecting psychiatric disorders in the elderly population
pp. 157s-157s(1)
Authors: Heun R.; Burkart M.; Maier W.; Bech P.

Lenght of first inpatient stay in psychiatric hospital
pp. 157s-157s(1)
Authors: Oiesvold T.; Saarento O.; Sytema S.; Christiansen L.; Gostas G.; Lonnerberg O.; Muus S.; Sandlund M.; Hansson L.

Validation of data on involuntary admissions to mental hospitals
pp. 157s-158s(2)
Authors: Poulsen H.D.; Munk-Jorgensen P.

A comparison of need for care between a group of ''heavy users'' of the psychiatric hospital and a group of ''difficult-to-place'' psychiatric patients in a Danish county
pp. 158s-158s(1)
Authors: Nielsen L.F.; Petersen L.; Werdelin G.

Translation of the scale ''the psychological well-being schedule'' (PGWB)
pp. 158s-158s(1)
Authors: Rasmussen N.-A.; Norholm V.

From nationally developed to internationally applicable measurements; the focus group process
pp. 158s-159s(2)
Authors: Knudsen H.C.; Welcher B.; Vazquez-Barquero J.L.; Gaite L.

An overview of the psychological consequences of torture and other related trauma
pp. 159s-159s(1)
Author: Kastrup M.

Children exposed to war, torture and other organized violence -- mental consequences
pp. 159s-159s(1)
Author: Montgomery E.

Sexual torture of women as a weapon of war -- the case of Bosnia-Herzegovina
pp. 159s-159s(1)
Author: Arcel L.T.

The stress of exile -- psychiatric consequences and beyond
pp. 159s-160s(2)
Author: Lecic-Tosevski D.

Help seeking and posttraumatic stress disorder symptoms in survivors of torture
pp. 160s-160s(1)
Authors: Wenzel T.; Griengl H.; Mirzaei S.; Meszaros K.; Kieffer W.; Lenz G.

Which subgroups of ADHD are clinically relevant?
pp. 160s-160s(1)
Author: Taylor E.

Dopamine D4 receptor gene polymorphism in children with attention deficit hyperactivity disorder (ADHD) -- a biological marker?
pp. 160s-160s(1)
Author: Seeger G.

Cerebellum in attention Deficit/Hyperactivity Disorder: an MRI morphometric study
pp. 160s-161s(2)
Authors: Berquin P.; Castellanos F.X.; Giedd J.N.; Hamburger S.D.; Rapoprt J.L.

The effectiveness of methylphenidate on attention processes in ADHD children
pp. 161s-161s(1)
Authors: Kemner C.; Jonkman L.M.; Verbaten M.N.; Van Engeland H.

The influence of methylphenidate on attention and impulsivity of ADHD-children: a pharmacological dissection study
pp. 161s-161s(1)
Author: van Engeland H.

Diagnosis and neurobiology of impulse control disorders
pp. 161s-162s(2)
Authors: Verhoeven W.M.A.; Tuinier S.

Stress hormones and impulse regulation
pp. 162s-162s(1)
Authors: Tuinier S.; Verhoeven W.M.A.; Van den Berg Y.W.M.M.; Thijssen J.H.H.

Behavioral phenotype and disturbed impulse control
pp. 162s-162s(1)
Authors: Curfs L.M.G.; Devriendt K.; Vogels A.; Fryns J.P.

Different diagnostic systems in describing aggression in mental retardation
pp. 162s-162s(1)
Authors: Tyrer S.P.; Moore P.B.

History of treatment systems and their consequences for the life of schizophrenics
pp. 162s-163s(2)
Author: de Girolamo G.

When and how does schizophrenia lead to social deficits?
pp. 163s-163s(1)
Authors: Hafner H.; Loffler W.; Maurer K.; an der Heiden W.

The influence of discrimination and stigma on the life of patients and their relatives
pp. 163s-163s(1)
Author: Leff J.

Do modern care and treatment improve the quality of life of schizophrenics and their relatives?
pp. 163s-164s(2)
Authors: Taylor R.E.; Leese M.; Clarkson P.; Holloway F.; Thornicroft G.

Schizophrenia as a lifetime disorder
pp. 164s-164s(1)
Authors: an der Heiden W.; Hafner H.

''Nations for mental health: a new WHO action programme on mental health for underserved populations
pp. 164s-164s(1)
Author: Saraceno B.

WFMH in world mental health: science, consumers and providers
pp. 164s-165s(2)
Author: de Vries M.W.

The contributions of the world psychiatric association to the resolution of mental health problems
pp. 165s-165s(1)
Author: Sartorius N.

Tackling the global burden of mental disorders
pp. 165s-165s(1)
Author: Jenkins R.

The Geneva initiative on psychiatry
pp. 165s-165s(1)
Author: Birley J.

Risk factors and psychosocial consequences in depression of octo- and nona-generians -- results of an epidemiological community study
pp. 165s-166s(2)
Authors: Meller I.; Fichter M.; Schroppel H.

Systematic approach to the depressions prognostic criteria
pp. 166s-166s(1)
Author: Grigorieva E.A.

Discriminative potential of anticipatory cognitions in different types of depression
pp. 166s-166s(1)
Authors: Cavaglia F.; Matos-Pires A.; Arriaga F.

Cognitive therapy for major depression in partial remission: preliminary findings
pp. 166s-166s(1)
Authors: Cornwall P.L.; Jenaway A.; Garland A.; Moore R.; Pope M.; Hayhurst H.; Teasdale J.; Scott J.; Paykel E.

Epidemiology of antidepressants
pp. 166s-167s(2)
Authors: Helgason T.; Zoega T.; Bjornsson J.K.; Tomasson H.

Depression and concomitant anxiety in the community: approach to treatment
pp. 167s-167s(1)
Author: Tylee A.

Vascular depression -- a concise concept?
pp. 167s-167s(1)
Author: Wetterling T.

Nature and nurture in affective disorder
pp. 167s-167s(1)
Author: Van Praag H.M.

Epidemiology and risk factors for Alzheimer's disease
pp. 168s-168s(1)
Author: Hofman A.

The pathological function of presenilin and APP in Alzheimer's disease
pp. 168s-168s(1)
Author: Haass C.

Early diagnosis and biological markers in Alzheimer's disease (AD) patients
pp. 168s-168s(1)
Author: Hock C.

Alzheimer's disease: potential of imaging and spectroscopic technique: PET, SPECT, DCS-MRI, MRI, MRS and FMRI. An overview
pp. 168s-169s(2)
Authors: Nedelec J.-F.J.; Bolo N.R.; Hode Y.; Macher J.-P.

Cholinergic treatment strategies in Alzheimer's disease
pp. 169s-169s(1)
Author: Giacobini E.

Anti-inflammatory and antioxidant therapeutic strategies in AD
pp. 169s-169s(1)
Author: Stahelin H.B.

Prevalence, incidence and syndrome stability of generalized and non-generalized social phobia in adolescents and adults
pp. 169s-169s(1)
Authors: Wittchen H.U.; Lepine J.P.

Psychosocial impairments and quality of life in social phobia
pp. 169s-170s(2)
Author: Katschnig H.

Familial aggregation and high risk study of social phobia
pp. 170s-170s(1)
Authors: Merikangas K.; Fenton B.; Stolar M.; Dierker L.

Development and anxiety disorders: contribution of familial aggregation
pp. 170s-170s(1)
Authors: Bouvard M.P.; Cabrol S.; Mouren-Simoni M.C.

The role of the family in early stages of generalized and non-generalized social phobia: a family and prospective longitudinal epidemiology study
pp. 170s-171s(2)
Authors: Lieb R.; Sonntag H.

Clinical course, phenomenology, and sequelae of social phobia in youth
pp. 171s-171s(1)
Author: Albano A.M.

Setting off a chainreaction the OCD school, an interdisciplinary educational program
pp. 171s-171s(1)
Author: Mindus P.

The OCD School: the patient and consumer perspective
pp. 171s-171s(1)
Author: Gill-Larsson B.

The OCD School: diagnostic aspects
pp. 171s-171s(1)
Author: Andreewitch S.

The OCD School: cognitive behaviour therapy
pp. 172s-172s(1)
Author: Bates S.

The OCD School: drug treatment
pp. 172s-172s(1)
Author: Waerner T.

Animal models of impulsivity and aggression
pp. 172s-172s(1)
Authors: Olivier B.; Bouwknecht A.

The use of serotonergic drugs in the treatment of impulse control disorders
pp. 172s-172s(1)
Authors: Carrasco J.L.; Saiz-Ruiz J.

Neuroleptics: are they effective in aggression?
pp. 173s-173s(1)
Author: Tyrer S.P.

The experimental measurement of human aggression
pp. 173s-173s(1)
Author: Bond A.J.

Symptom dimensions, clusters and subtypes of schizophrenia prior to and 5 years after first admission
pp. 173s-173s(1)
Authors: Loffler W.; Hafner H.

Cognitive impairments in subtypes of schizophrenia
pp. 174s-174s(1)
Authors: Brazo P.; Halbecq I.; Marie R.M.; Segard L.; Delamillieure P.; Thibaut F.; Langlois-Thery S.; Van Der Elst A.; Vasse T.; Petit M.; Dollfus S.

German version of the Snaith-Hamilton-Pleasure-Scale (SHAPS-D): assessing anhedonia in schizophrenic patients
pp. 174s-174s(1)
Authors: Franz M.; Meyer T.; Ehlers F.; Runzheimer P.; Gallhofer B.

Negativ symptoms in schizophrenia: predictive value of sex, age, subtypes and concomitant psychopathological symptoms
pp. 174s-174s(1)
Authors: Schutz C.G.; Bottlender R.; Strausz A.; Moller H.J.

Acute transient psychoses: a subgroup of schizophrenia?
pp. 174s-175s(2)
Authors: Marneros A.; Pillmann F.; Haring A.

The cochrane schizophrenia group
pp. 175s-175s(1)
Authors: Roberts L.; Adams C.

Patient and relative education in community psychiatry; a randomized trial regarding it's usefulness
pp. 175s-175s(1)
Authors: Merinder L.B.; Viuff A.G.; Laugesen H.D.; Clemmensen K.; Misfelt S.; Espensen B.

Mental health research & policy in Europe
pp. 175s-175s(1)
Author: Ghodse H.

The Italian psychiatric reform. A study of its evolution through a scientific national congress
pp. 176s-176s(1)
Author: Furlan P.M.

Psychiatric research and development: a Danish perspective
pp. 176s-176s(1)
Author: Rosenberg R.

Psychiatric research in Finland. Future prospects
pp. 176s-176s(1)
Author: Salokangas R.K.R.

Validity of nosological classification
pp. 177s-177s(1)
Author: Smolik P.

Genetic research in relation to ICD-10 and DSM III/IV classification
pp. 177s-177s(1)
Author: Maier W.

Modern nosology: how do biological findings and therapy fit?
pp. 177s-177s(1)
Author: Ackenheil M.

Classificatory obstacles in biological psychiatry and psychopharmacology
pp. 177s-178s(2)
Author: Van Praag H.M.

Affective disorders in the postnatal period and the premenstruum: biological mechanisms
pp. 178s-178s(1)
Author: Wieck A.

A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression
pp. 178s-178s(1)
Author: Appleby L.

Neurodevelopment of children exposed in utero to antidepressant drugs
pp. 178s-179s(2)
Authors: Nulman I.; Rovet J.; Stewart D.E.; Wolpin J.; Gardner H.A.; Theis J.G.W.; Kulin N.; Koren G.

The pharmacological treatment of premenstrual dysphoria
pp. 179s-179s(1)
Author: Eriksson E.

The history and development of community psychiatry
pp. 179s-179s(1)
Authors: Thornicroft G.; Tansella M.

Time to slow down the decentralization process?
pp. 179s-180s(2)
Author: Munk-Jorgensen P.

Quality of life for patients in the community
pp. 180s-180s(1)
Author: Katschnig H.

The impact of community care upon families
pp. 180s-180s(1)
Authors: Schene A.H.; van Wijngaarden B.

Deinstitutionalisation and schizophrenia in Finland. Results of the DSP-project
pp. 180s-181s(2)
Authors: Salokangas R.K.R.; Honkonen T.

Psychological and psychopathological concepts of impulsiveness and impulse control disorders
pp. 181s-181s(1)
Authors: Herpertz S.; Sass H.

Testosterone as an indicator of an altered 5-HT responsivity in aggressive subjects
pp. 181s-181s(1)
Authors: Netter P.; Hennig J.; Meier B.; Rohrmann S.

Cognitive psychophysiology of impulsivity and loss of control
pp. 181s-181s(1)
Authors: Jouvent R.; Pierson A.

Familial influences on impulsive behavior: evidence from a twin study
pp. 182s-182s(1)
Authors: Tsuang M.T.; Lyons M.

Animal models
pp. 182s-182s(1)
Author: Olivier B.

An update of pharmacotherapy of impulsive behaviour
pp. 182s-182s(1)
Authors: Ackenhell M.; Bondy B.; Muller N.; Schwarz M.

Sexual dysfunction and psychopharmacology
pp. 182s-183s(2)
Author: Segraves R.T.

The relevance of psychotropics-induced sexual dysfunction within the ADR voluntary reporting system in Germany
pp. 183s-183s(1)
Authors: Muller-Oerlinghausen B.; Ringel I.; Munter K.-H.

Neuroanatomy and neurobiology of the central serotonergic system in sexual functioning
pp. 183s-183s(1)
Author: Waldinger M.D.

Effects of agents active at the dopaminergic system on sexual function
pp. 183s-183s(1)
Authors: Zemishlany Z.; Aizenberg D.; Weizman A.

Treatment issues in sexual dysfunction associated with psychopharmacological agents
pp. 184s-184s(1)
Author: Balon R.

Conceptual and methodological principles of the whoqol
pp. 184s-184s(1)
Author: Orley J.

The quality of life of people living with HIV/AIDS
pp. 184s-184s(1)
Author: Billington D.R.

WHOQOL-BREF in the first Danish applicability studies
pp. 184s-184s(1)
Authors: Norholm V.; Bech P.

Quality of life in cronic fatigue syndrome patients
pp. 184s-185s(2)
Authors: Van Heck G.L.; De Vries J.

Quality of life among Israeli Arabs and Israeli Jews
pp. 185s-185s(1)
Authors: Amir M.; Taya M.

MDMA-users in a specialised adolescent psychiatric out-patient service
pp. 185s-185s(1)
Authors: Bilke O.; Knolker U.

Sociodemographic and psychopathologic variables at the children and youth with the substance use
pp. 185s-185s(1)
Author: Skodacek I.

Homeless alcoholics prevalence of psychiatric comorbidity and outcome of drinking
pp. 185s-186s(2)
Authors: Tomasson K.; Vaglum P.

Dual diagnosis: a survey in Paris area
pp. 186s-186s(1)
Authors: Launay C.; Perdereau F.; Antoine D.; Petitjean F.

Determinants of reported amnesia for the offence in 246 defendants
pp. 186s-186s(1)
Authors: Pillmann F.; Ullrich S.; Draba S.; Sannemuller U.; Marneros A.

Cross-cultural comparison of lay versus professional concepts of alcohol use. A nine-culture study
pp. 186s-186s(1)
Authors: Vrasti R.; Trotter R.

Does psychiatric morbidity have a role in increasing smoking levels in the community?
pp. 186s-187s(2)
Authors: Ismail K.; de Stavola B.; Sloggett A.

Genetic aspects of bipolar disorders
pp. 187s-187s(1)
Authors: Mendlewicz J.; Massat I.

Assortative mating in bipolar disorder
pp. 187s-187s(1)
Authors: Fenton B.T.; Preisig M.; Ferrero F.

Epidemiology, validity and comorbidity of milder bipolar subgroups
pp. 187s-187s(1)
Author: Angst J.

Mixed states: is there a interaction between depressive symptoms, gender and affective temperaments?
pp. 188s-188s(1)
Author: Hantouche E.G.

The course and outcome in bipolar affective disorder
pp. 188s-188s(1)
Authors: Gjerris A.; Christensen E.M.; Larsen J.K.

Long-term outcome of lithium prophylaxis in bipolar disorder
pp. 188s-188s(1)
Author: Maj M.

Psychopathology of negative-positive dichotomy of schizophrenic symptoms
pp. 188s-189s(2)
Author: Parnas J.

Quality of life: symptoms - side effects - social performance - mood
pp. 189s-189s(1)
Author: Bech P.

Antipsychotics: will the atypicals improve the patients' quality of life?
pp. 189s-189s(1)
Author: Naber D.

Community psychiatry: the challenge of coordination and focus
pp. 189s-189s(1)
Author: Burns T.

The assessment of the quality of care using some pharmacoeconomic parameters
pp. 189s-190s(2)
Authors: Altamura A.C.; Percudani M.

Experiences with screening instruments for personality disorders
pp. 190s-190s(1)
Author: Ekselius L.

Personality disorders -- what is the experience and preferred treatment among Norwegian specialists
pp. 190s-190s(1)
Author: Narud K.

General practitioners' barriers on talking about alcohol with their patients
pp. 190s-190s(1)
Author: Barfod S.

Recognition of and early intervention in alcohol abusers in general hospital and private practices in Germany
pp. 191s-191s(1)
Authors: John U.; Rumpf H.J.; Hapke U.; Hill A.; Veltrup C.

Outcome of brief intervention for alcohol problems in primary care: a critical review
pp. 191s-191s(1)
Author: Chick J.

Comorbidity problems and addiction; implication for detection and treatment
pp. 191s-191s(1)
Authors: Geerlings P.J.; van den Brink W.

The assessment of syndromes in schizophrenia: current status and future perspectives
pp. 191s-191s(1)
Author: Moller H.-J.

The assessment of depressive syndromes: current status and future perspectives
pp. 191s-192s(2)
Author: Stieglitz R.-D.

The AMDP-depression-scale: a new comprehensive rating scale for the assessment of depressive symptomatology
pp. 192s-192s(1)
Author: Ahrens B.

The AMDP-obsessive-compulsive scale: a new instrument to assess OCD-related symptoms
pp. 192s-192s(1)
Authors: Grabe H.-J.; Thiel A.; Kathmann N.; Boerner R.; Hoff P.; Freyberger H.J.

Assessment of noncognitive psychopathology in Alzheimer's dementia
pp. 192s-192s(1)
Author: Rosler M.

Predictors of multiple comorbidity in patients with panic disorder and agoraphobia
pp. 194s-194s(1)
Authors: Latas M.; Starcevic V.; Trajkovic G.; Bogojevic G.

Treatment options in social phobia
pp. 194s-194s(1)
Author: Westenberg H.G.M.

Family history, personality and comorbid symptoms in panic disorder
pp. 194s-195s(2)
Authors: Arriaga F.; Abreu M.; Matos-Pires A.; Cavaglia F.; Lara E.

Cognitive therapy of panic disorder and social phobia -- a follow-up study
pp. 195s-195s(1)
Authors: Rosenberg N.K.; Hougaard E.; Falk T.; Elsass P.

Behavior therapy and pharmacotherapy in the treatment of panic disorders and obsessive-compulsive disorders
pp. 195s-195s(1)
Authors: Lemmer W.; Strausz H.W.; Agelink M.W.

OCD: from neurasthenia to neuroscience
pp. 195s-195s(1)
Author: Zohar J.

Short and long term treatment of OCD
pp. 196s-196s(1)
Author: Montgomery S.A.

Co-morbidity of OCD, panic disorder and depression -- a diagnostic dilemma and clinical challenge
pp. 196s-196s(1)
Authors: Altamura A.C.; Mannu P.

Biological markers in OCD and predictors of response
pp. 196s-196s(1)
Author: Marazziti D.

OCD spectrum disorders -- from impulsivity to compulsivity
pp. 196s-196s(1)
Authors: Hollander E.; DeCaria C.M.; Cartwright C.

EEG reactivity mapping in first episode, neuroleptic-naive schizophrenics and relations to psychopathology
pp. 196s-197s(2)
Author: Koukkou M.

EEG mapping before and after antipsychotic treatment in chronic and first-episode schizophrenics
pp. 197s-197s(1)
Authors: Galderisi S.; Mucci A.; Maj. M.

EEG mapping in positive and negative schizophrenia and under different neuroleptics
pp. 197s-197s(1)
Author: Saletu B.

Deviant microstates ('atoms of thought') in brain electric field sequences of acute schizophrenics
pp. 197s-198s(2)
Author: Lehmann D.

Functional asymmetries of the brain in schizophrenia
pp. 198s-198s(1)
Authors: Strik W.K.; Heidrich A.; Fallgatter A.J.; Mueller T.J.

EEG FFT approximation source locations in schizophrenia
pp. 198s-198s(1)
Authors: Dierks T.; Maurer K.

The mini international neuropsychiatric interview
pp. 198s-198s(1)
Authors: Lecrubier Y.; Sheehan D.; Hergueta T.; Weiller E.

A Spanish validation study of the mini international neuropsychiatric interview
pp. 198s-199s(2)
Author: Bobes J.

The mind: an update on rating scales for the mini compendium
pp. 199s-199s(1)
Author: Schutze T.

Prime-MD: the ICD-10 version
pp. 199s-199s(1)
Author: Malt E.A.

Prime-MD: from DSM-IV to ICD-10
pp. 199s-200s(2)
Author: Katschnig H.

Epidemiology and course of panic disorder
pp. 200s-200s(1)
Author: Katschnig H.

Components in 5-HT neurotransmission in depression and anxiety
pp. 200s-200s(1)
Authors: Deakin J.F.W.; Mortimore C.; Strickland P.L.; Anderson I.M.

Neurobiology of panic disorder
pp. 200s-200s(1)
Authors: den Boer J.A.; van Vliet I.M.; van Megen H.J.G.M.; Westenberg H.G.M.

New findings in the pharmacological treatment of panic disorder
pp. 201s-201s(1)
Author: Rosenberg R.

Psychological and biological response prediction to pharmacotherapy in panic disorder?
pp. 201s-201s(1)
Authors: Slaap B.R.; Den Boer J.A.

Comorbidity and its clinical relevance in panic disorder
pp. 201s-201s(1)
Authors: Cassano G.B.; Pini S.

Recent changes in coercive help of minors in Finland
pp. 201s-202s(2)
Author: Kaivosoja M.

Case finding in arrested juvenile delinquents
pp. 202s-202s(1)
Authors: Doreleijers T.A.H.; Bijl B.

Juvenile sexual delinquents
pp. 202s-202s(1)
Authors: Hummel P.; Thomke V.; Oldenburger H.; Specht F.

Evaluation and treatment of juvenile delinquents
pp. 202s-202s(1)
Author: Bailey S.

Detection of depressive symptoms in the elderly: the impact of cognitive decline upon the performance of screening instruments
pp. 203s-203s(1)
Authors: Papassotiropoulos A.; Heun R.

The pseudodementia scale
pp. 203s-203s(1)
Authors: Yousef G.; Ryan W.; Lambert T.; Kellett J.

Anhedonia and psychomotor changes in depression
pp. 203s-203s(1)
Authors: Lemke M.R.; Puhl P.; Koethe N.; Mieth B.; Winkler T.

Recovery in affective disorder -- a case register study
pp. 204s-204s(1)
Author: Kessing L.V.

Mortality in adolescents admitted with a diagnosis of affective disorder (depression and bipolar disorder)
pp. 204s-204s(1)
Authors: Lorenzen C.; Thomsen P.H.

Treatment of acute manic episodes with valproate as an adjunct to neuroleptic medication
pp. 204s-204s(1)
Authors: Muller-Oerlinghausen B.; Retzow A.

A comparison of symptoms following treatment interruption: evidence from a randomized, double-blind trial with fluoxetine, sertraline, and paroxetine
pp. 204s-205s(2)
Authors: Fava M.; Rosenbaum J.; Hoog S.; Krebs W.; Dillon J.

Optimal use of classical (typical) antipsychotic drugs
pp. 205s-205s(1)
Author: Branford D.

Optimal use of atypical antipsychotics
pp. 205s-205s(1)
Author: Paton C.

Optimal use of clozapine
pp. 205s-205s(1)
Author: Taylor D.

Optimal use of mood stabilising agents
pp. 205s-205s(1)
Author: Haygarth L.

Optimal use of antidepressants
pp. 205s-205s(1)
Author: Donoghue J.

Optimising compliance with treatment
pp. 206s-206s(1)
Author: Bazire S.

Definition criteria for treatment resistant depression
pp. 206s-206s(1)
Author: Souery D.

Clinical and epidemiological characteristics of resistant depression
pp. 206s-206s(1)
Author: Lecrubier Y.

Neurobiology of resistant depression
pp. 206s-207s(2)
Authors: Zohar J.; Sasson Y.; Chopra M.; Iancu I.; Gross R.

Pharmacodynamics and pharmacokinetics as a possible causality in resistant depression
pp. 207s-207s(1)
Author: Racagni G.

General therapeutic strategies in TRD: limitations and prospects
pp. 207s-207s(1)
Author: Montgomery S.A.

Augmentation strategies in treatment resistant depression: preclinical and clinical aspects
pp. 207s-208s(2)
Authors: de Montigny C.; Blier P.

Adolescent liaison psychiatry: ethical and legal issues
pp. 208s-208s(1)
Author: Barbosa A.

Prevention and early treatment of substance abuse: ethical aspects
pp. 208s-208s(1)
Author: Bailly D.

Early developmental predictors of adolescent psychopathology
pp. 208s-208s(1)
Authors: Ram A.; Kikinzon L.; Ladame F.; Braconnier A.; Weizman A.; Tyano S.

A comparative multinational epidemiological study of adolescent outpatient clinics
pp. 208s-209s(2)
Authors: Kikinzon L.; Ram A.; Ladame F.; Braconnier A.; Weizman A.; Tyano S.

The neurobiology of anxiety disorders
pp. 209s-209s(1)
Author: Westenberg H.G.M.

The treatment of generalized anxiety disorder
pp. 209s-209s(1)
Author: Sheehan D.V.

Prevalence of, screenig for and GPS' recognition of somatoform disorder in primary care
pp. 209s-210s(2)
Authors: Fink P.; Engberg M.; Sorensen L.; Holm M.; Munk-Jorgensen P.

Psychiatric morbidity in a medical department
pp. 210s-210s(1)
Authors: Hansen M.S.; Fink P.; Oxhoj M.L.; Eriksen M.; Sondergaard L.

Screening for somatoform disorder in medical outpatient clinics
pp. 210s-210s(1)
Author: Peveler R.C.

Patients presenting to cardioligists with the complaint of palpitations
pp. 210s-211s(2)
Author: Mayou R.

Migraine and psychiatric disorders. A population and register based investigation
pp. 211s-211s(1)
Authors: Sorensen L.; Russell M.

Action as a determinant in stimulus processing as assessed by the conditioned taste aversion paradigm in rats
pp. 211s-211s(1)
Authors: Fouquet N.; Sandner G.

Indicators of chronic immune activation in schizophrenia
pp. 211s-211s(1)
Authors: Sluzewska A.; Bosmans E.; Rybakowski J.; Sobieska M.

Are the structural brain abnormalities in schizophrenia mediated by pregnancy and birth complications?
pp. 211s-212s(2)
Authors: Fearon P.; O'Connell P.; Aquino P.; Frangou S.; Rifkin L.; Murray R.M.

Harm avoidance and 5-HT2A receptors: a brain imaging study
pp. 212s-212s(1)
Authors: D'haenen H.; Baeken C.; Flamen P.; Mertens J.; Terriere D.; Chavatte K.; Boumon R.; Bossuyt A.

Amisulpride in acutely ill schizophrenic patients: efficacy, safety and related social adaptation
pp. 212s-212s(1)
Authors: Chabannes J.P.; Gerard D.; Chignon J.M.

Dopamine D₁ and D₄-like receptors in untreated schizophrenic patients and healthy controls
pp. 212s-212s(1)
Authors: Klimke A.; Boy C.; Eickhoff M.; Herzog H.; Holschbach M.; Muhlensiepen H.; Weckesser M.; Rota-Kops E.; Sonnenberg F.; Gaebel W.; Markstein R.; Stocklin G.; Coenen H.H.; Muller-Gartner H.W.

Tardive dyskinesia and dopamine 3 receptor gene mutation
pp. 213s-213s(1)
Authors: Aschauer H.N.; Scharfetter J.; Fuchs K.; Gerhard E.; Gebhardt C.; Lenzinger E.; Meszaros K.; Hornik K.; Sieghart W.; Kasper S.

Therapeutic drug monitoring routine in general psychiatry
pp. 213s-213s(1)
Authors: Boermans J.A.J.; Tuinier S.; Verhoeven W.M.A.; Noten J.B.G.M.; Jagmont T.M.; Van den Berg Y.W.M.M.

Auditory event related potentials and obsessive compulsive symptoms
pp. 213s-213s(1)
Authors: Bersani G.; Arcangeli T.; Venturi P.; Valchera A.; Taddei I.

Epidemiology of obsessive-compulsive disorder in young adolescents -- a Polish perspective
pp. 213s-214s(2)
Authors: Brynska A.; Wolanczyk T.; Goszczynska B.

Hallucinatory phenomena in eating disorders: function and significance
pp. 214s-214s(1)
Authors: Moscianese K.; Filesi S.; Ciocca A.

Alterations of autonomic cardiac control in anorexia nervosa
pp. 214s-214s(1)
Author: Rechlin T.

Bone mineral density in adolescent girls with anorexia nervosa
pp. 214s-214s(1)
Authors: Jagielska G.; Tomaszewicz-Libudzic C.; Komender J.; Wolanczyk T.; Przedlacki J.; Ostrowski K.

Prevalence of bulimia nervosa in middle adolescence
pp. 214s-215s(2)
Authors: Kaltiala-Heino R.; Rissanen A.; Rantanen P.; Rimpela M.

Critical issues in the classification of somatoform disorders
pp. 215s-215s(1)
Author: Sartorius N.

Who study: somatoform disorders in general practice, an epidemiological survey
pp. 215s-215s(1)
Author: Lecrubier Y.

Chronic fatigue syndrome
pp. 215s-215s(1)
Author: Wessely S.

The biology and therapy of fibromyalgia syndrome -- overlaps to depression
pp. 216s-216s(1)
Author: Ackenheil M.

Clinical heterogeneity of schizophrenia: a commonplace frequently ignored
pp. 216s-216s(1)
Author: Ungvari G.S.

The different genetic background of schizophrenic subgroups
pp. 216s-216s(1)
Authors: Beckmann H.; Franzek E.; Stober G.

New findings in the aetiology of cycloid psychoses
pp. 216s-217s(2)
Authors: Pfuhlmann B.; Franzek E.

Electrophysiological evidence for subgrouping of schizophrenia
pp. 217s-217s(1)
Authors: Strik W.K.; Fallgatter A.J.; Ruchsow M.; Mueller T.J.

Maternal gestational infections in the etiology of schizophrenic psychoses
pp. 217s-217s(1)
Author: Stober G.

Alzheimer's disease, genetic and environmental factors
pp. 217s-218s(2)
Author: Van Duijn C.M.

Genetic and environmental factors in schizophrenia
pp. 218s-218s(1)
Author: McGuffin P.

Status of the search for genes involved in bipolar affective disorder
pp. 218s-218s(1)
Author: Ewald H.

Management of first-episode patients
pp. 218s-219s(2)
Author: Kahn R.S.

Challenges in patient management
pp. 219s-219s(1)
Author: Pickar D.

Mood and related symptoms in schizophrenia
pp. 219s-219s(1)
Author: Montgomery S.A.

Cognitive deficits in schizophrenia
pp. 219s-219s(1)
Author: Breier A.

Quality of life and re-integration of chronically ill patients
pp. 219s-219s(1)
Author: Revicki D.A.

Lithium and antiepileptics in the treatment of bipolar disorder
pp. 219s-220s(2)
Author: Young A.H.

Olanzapine versus placebo in the treatment of acute mania
pp. 220s-220s(1)
Authors: Tohen M.; Sanger T.M.; Tollefson G.D.

The place of antipsychotics in the therapy of bipolar disorder
pp. 220s-220s(1)
Author: Licht R.W.

Depression in psychosis and bipolar disorder
pp. 220s-220s(1)
Author: Gjerris A.

Treatment approaches to posttraumatic stress disorder
pp. 221s-221s(1)
Author: Davidson J.

Anger attacks in depressed outpatients and their response to fluoxetine
pp. 221s-221s(1)
Authors: Fava M.; Rosenbaum J.F.; McCarthy M.; Pava J.; Steingard R.; Bless E.

Treatment options for the pharmacotherapy of eating disorders
pp. 221s-221s(1)
Author: Kasper S.

Depression in children and adolescents
pp. 221s-222s(2)
Author: Emslie G.J.

SSRIs in the treatment of PMDD: an update
pp. 222s-222s(1)
Author: Steiner M.

The debilitating burden of depression
pp. 222s-222s(1)
Author: Sartorius N.

Evidence based medicine in depression: the difference between theory and practice
pp. 222s-222s(1)
Author: Linden M.

Quality improvement in the treatment of depression through education
pp. 222s-223s(2)
Author: Rutz W.

Sharing responsibility for improved care
pp. 223s-223s(1)
Author: Hogenboom R.

What evidence should be presented through a CD-ROM program?
pp. 223s-223s(1)
Author: Van Praag H.M.

Trauma
pp. 223s-223s(1)
Author: Davidson J.

Fear
pp. 223s-224s(2)
Author: Walker J.R.

Panic
pp. 224s-224s(1)
Author: Pollack M.

Obsession
pp. 224s-224s(1)
Author: Thomsen P.H.

Impulsivity
pp. 224s-224s(1)
Author: Hollander E.

Ziprasidone: from receptor profile to patient outcomes -- a review of short-term efficacy studies
pp. 225s-225s(1)
Author: Wiesel F.A.

The impact of side effects -- patient, family and physician concerns
pp. 225s-225s(1)
Author: Fleischhacker W.W.

A basis for optimism -- the implications of long-term treatment
pp. 225s-226s(2)
Author: Schooler N.

Achieving effective treatment alliances -- introducing a new patient, carer and care team programme
pp. 226s-226s(1)
Author: Waerner T.

Drug addiction and borderline personality
pp. 227s-227s(1)
Authors: Carreau M.C.; Sztulman H.

The mariholic adolescents: system of actions and borderline personality
pp. 227s-227s(1)
Authors: Bernoussi A.; Sztulman H.

What does reveal abstinence about the functions of addictive behaviors?
pp. 228s-228s(1)
Authors: Catteeuw M.; Sztulman H.

Towards an addiction general model?
pp. 228s-228s(1)
Authors: Loonis E.; Sztulman H.

Alternative strategies of opiate detoxification: evaluation of the so-called ultra rapid detoxification
pp. 228s-228s(1)
Authors: Scherbaum N.; Klein S.; Kienbaum P.; Peters J.; Gastpar M.

NMDA receptors in alcoholism: pharmacological challenge with the non-competitive NMDA antagonist dextromethorphan
pp. 229s-229s(1)
Authors: Schutz C.G.; Soyka M.

The effects of granisetron on heroin withdrawal syndrome
pp. 229s-229s(1)
Author: Fodor M.

Is therapeutic work on inpatient relapses during qualified detoxification practicable and helpful? a single case observation
pp. 229s-229s(1)
Author: Lauer G.

The installation of a psychiatric out-patient drug and addiction service for adolescents -- first results on clinical and institutional problems
pp. 229s-229s(1)
Authors: Bilke O.; Knolker U.

Drug use and psychological profiles in military conscripts
pp. 230s-230s(1)
Authors: Saiz P.A.; Gonzalez M.P.; Bousono M.; Bobes J.

Relationship between chronic alcoholism, peripheral polyneuropathy (PNP) and cardiac autonomic neuropathy (CAN)
pp. 230s-230s(1)
Authors: Agelink M.W.; Malessa R.; Weisser U.; Zeit T.; Bertling R.; Ullrich H.; Majewski T.; Lemmer W.

Substance abuse and psychiatric comorbidity
pp. 230s-230s(1)
Authors: Shah C.; White J.; Chen S.; Simitian L.

The impact of craving on termination of alcohol abstinence
pp. 230s-231s(2)
Authors: Veltrup C.; Wetterling T.

Measuring craving in alcoholics: a comparison of the german versions of ACQ, OCDS, vas and LCRR
pp. 231s-231s(1)
Authors: Schutz C.G.; Preusz U.; Koch J.; Soyka M.

Variability of tobacco addiction and narcissistic disposition: a comparison of non-smokers and smokers undergoing stop smoking treatment
pp. 231s-231s(1)
Authors: Fernandez L.; Sztulman H.

Delinquency and drugs comsumption: some risk factors in youths male
pp. 231s-232s(2)
Authors: Quiroga M.; Garcia J.L.; Lopez A.; Pagan C.

Psychological particularities of computerization in posttotalitarien society (10-years follow-up study)
pp. 232s-232s(1)
Author: Melnik E.

A study on injecting behaviour in substance users
pp. 232s-232s(1)
Author: Kutsenok I.

Lerivon efficacy in alcoholism
pp. 232s-232s(1)
Author: Ivanets N.N.

Cholecystokinin in the treatment of alcohol and opiate withdrawal syndromes neurochemical mechanisms
pp. 232s-232s(1)
Author: Anokhina I.P.

Alcoholic consumption, alcohol-related consequences and alcoholic policy in Russia (1945-1996)
pp. 232s-233s(2)
Author: Nemtsov A.V.

Drinking patterns in different professional groups in the european north of russia (epidemiological study)
pp. 233s-233s(1)
Authors: Kalinin A.; Sidorov P.

Hyperbaric oxygentaion effect and the mechanisms of action in alcohol abuse and drug addiction
pp. 233s-233s(1)
Authors: Epifanova N.; Romasenko M.; Epifanov I.

Serotonin content in platelets and in blood plasma in the dynamics of alcohol delirium development
pp. 233s-233s(1)
Authors: Drozdov A.Z.; Kogan B.M.

Catecholamine conjugated forms in alcohol psychoses
pp. 234s-234s(1)
Authors: Kogan B.M.; Drozdov A.Z.; Filatova T.S.; Mankovsky I.V.

Psychological and clinical factors predicting alcohol abstinence during 16-weeks treatment with lithium carbonate
pp. 234s-234s(1)
Authors: Kosmowski W.; Ziolkowski M.; Rybakowski J.; Volpicelli J.R.

Acamprosate in alcohol dependence: a placebo-controlled study in a comprehensive post-detoxification program
pp. 234s-234s(1)
Authors: Tempesta E.; Janiri L.; Bignamini A.; Chabac S.; Potgieter A.

Psychological and clinical factors predicting alcohol abstinence during 16-weeks treatment with naltrexone
pp. 234s-235s(2)
Authors: Ziolkowski M.; Rybakowski J.; Kosmowski W.; Volpicelli J.R.

A MMPI-based two types of alcoholics -- results of cluster analysis
pp. 235s-235s(1)
Authors: Hauser J.; Zakrzewska M.

Addiction tertiary prevention programme in the island of Gozo - the Minessota model modified for local needs
pp. 235s-235s(1)
Authors: Grech A.; Cordina E.; Xerri N.

Relationship between obsessive-compulsive disorder and the HD mutation in an informative pedigree
pp. 235s-235s(1)
Authors: Fusco R.; Mennella R.; Ragone M.A.; Daniele F.; De Marchi N.

SSRIs and sexual obsessions
pp. 236s-236s(1)
Authors: Kaufman K.R.; Gerner R.H.

Comorbidity of obssesive compulsive symptoms with childhood stuttering
pp. 236s-236s(1)
Authors: Avci A.; Diler R.S.

The reliability and validity of polish versions of the Leyton Obsessional Inventory-Child version and the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
pp. 236s-236s(1)
Authors: Brynska A.; Wolanczyk T.; Goszczynska B.

Electroconvulsive therapy in severe obsessive-compulsive disorder
pp. 236s-237s(2)
Author: Garrido A.

Clinical variants of obsessive-compulsive disorders of organic genesis
pp. 237s-237s(1)
Authors: Maksoutova A.; Jeleznova E.; Sokolova L.

Phenomenology of obsessive-compulsive symptoms in non-referred polish adolescents
pp. 237s-237s(1)
Authors: Brynska A.; Wolanczyk T.; Goszczynska B.

Creative therapy and social phobia. A naturalistic case-study
pp. 237s-237s(1)
Author: Gois C.

Paroxetine in severe social phobia
pp. 237s-238s(2)
Authors: Montgomery S.A.; Pitts C.; Oakes R.; Hunter B.; Gergel I.

The symptom structure of generalized anxiety disorder revisited
pp. 238s-238s(1)
Authors: Starcevic V.; Bogojevic G.

Anxiety disorders and somatic illnesses
pp. 238s-238s(1)
Authors: Panagoulias E.; Papadopoulos P.; Malidelis D.

Once-daily venlafaxine XR versus buspirone in outpatients with generalized anxiety disorder
pp. 238s-238s(1)
Authors: Aguiar L.; Haskins J.T.; Rudolph R.

Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder
pp. 238s-239s(2)
Authors: Haskins J.T.; Rudolph R.; Aguiar L.

Kava-kava and psychophytopharmaca: differential therapy in generalized anxiety disorders
pp. 239s-239s(1)
Authors: Lemmer W.; Agelink M.W.

Risk of depression after breast cancer
pp. 239s-239s(1)
Authors: Hjerl K.; Olsen E.W.; Keiding N.; Mortensen P.B.; Sorensen T.; Jorgensen T.

Suicidal risk after breast cancer
pp. 239s-239s(1)
Authors: Hjerl K.; Olsen E.W.; Keiding N.; Mortensen P.B.; Sorensen T.; Jorgensen T.

Affective spectrum disorders among the patients with diabetes mellitus
pp. 239s-240s(2)
Author: Piatnitski N.

Coping strategies and psychological morbility in asymptomatic, symptomatic and aids patients
pp. 240s-240s(1)
Authors: Soler-Vinolo M.; Soler P.; Carretero M.D.; Martin C.; Soler-Arrebola M.; A-Nacle J.P.

Social support among different HIV positive risk groups
pp. 240s-240s(1)
Authors: Soler P.; Martin C.; Carretero M.D.; Soler-Vinolo M.; Soler-Arrebola M.

Influence of interpersonal psychotherapy (IPT) on psychosocial variables and immune status of depressed HIV-positive patients
pp. 240s-240s(1)
Authors: Gruettert T.; Alm B.; Henn F.A.

Interpersonal psychotherapy (IPT) as a treatment for depressed HIV-positive patients: focus, psychosocial variables, outcome
pp. 240s-241s(2)
Authors: Gruettert T.; Alm B.; Henn F.A.

Locus of control in insulin-dependent diabetic patients
pp. 241s-241s(1)
Authors: Hermoso E.; Martin C.; Soler P.; Carretero M.D.; Fernandez A.; Soler M.

Coping strategies among patients whith diabetes mellitus
pp. 241s-241s(1)
Authors: Martin C.; Hermoso E.; Soler P.; Carretero M.D.; Fernandez A.; Soler M.

Longitudinal study of the psychosocial adjustment to the HIV infection
pp. 241s-241s(1)
Authors: Morer A.; Blanch J.; Gasol M.; Rousaud A.; Reig M.; Cirera E.; Valdes M.

Patients with moderate cerebral and vascular disorders in centre of social care
pp. 241s-242s(2)
Authors: Polishuk Y.; Golubtsova L.

Abstract(s)
pp. 242s-242s(1)
Authors: Martynova N.; Krasnov V.; Podrezova L.; Tchereiskaia N.

Abstract(s)
pp. 242s-242s(1)
Authors: Martynova N.; Krasnov V.; Podrezova L.; Tchereiskaia N.

Genetic association study of promoter region polymorphisms in tryptophan hydroxylase and serotonin transporter genes with bipolar disorder
pp. 242s-242s(1)
Authors: Manzi C.; Bouanani S.; Gonnelli C.; Tiano L.; Armani A.; Sarno N.; Masala I.; Rotondo A.; Dell'Osso L.

Emotional distress and catastrophic cognitions in HIV infection
pp. 242s-243s(2)
Authors: Ouakinin S.; Goncalves G.; Nabais I.; Figueira M.L.; da Fonseca J.L.S.

Pharmacological treatment in HIV-possitive patients with depression
pp. 243s-243s(1)
Authors: Morer A.; Blanch J.; Gasol M.; Cirera E.; Valdes M.

Comparison between the hospital anxiety and depression scale and the beck depression inventory in detecting depression in HIV infected patients
pp. 243s-243s(1)
Authors: Morer A.; Blanch J.; Gasol M.; Cirera E.; Valdes M.

Can SSRI induce mania?
pp. 243s-243s(1)
Authors: Di Sciascio G.; Calo P.; Clemente P.

Amantadine and depression
pp. 244s-244s(1)
Authors: Huber T.J.; Dietrich D.E.; Emrich H.M.

Amantadine to augment antidepressive medication in borna disease virus (BDV) infected patients with affective disorders
pp. 244s-244s(1)
Authors: Dietrich D.E.; Bode L.; Spannhuth C.W.; Huber T.J.; Ludwig H.; Emrich H.M.

Bipolar II versus unipolar atypical depression in private practice outpatients
pp. 244s-244s(1)
Author: Benazzi F.

Bipolar versus unipolar psychotic depression in private practice outpatients
pp. 244s-244s(1)
Author: Benazzi F.

Clinical experience with gabapentin in patients with bipolar disorder: results of an open label study
pp. 244s-245s(2)
Authors: Cabras P.L.; Hardoy J.; Hardoy C.

The niacin skin patch test as a diagnostic aid in primary care psychiatry
pp. 245s-245s(1)
Authors: Ward P.E.; Glen E.M.T.; Sutherland J.; MacGregor A.; Douglas J.D.M.; Glen A.I.M.

Chronobiological model of mood stabilizers effect
pp. 245s-245s(1)
Author: Mosolov S.

Characteristics of mixed and pure mania in bipolar disorder with psychotic features
pp. 245s-246s(2)
Authors: Pini S.; Mastrocinque C.; Manzi C.; Saettoni M.; Vignoli S.; Papasogli A.; Marcacci G.; Cassano G.B.; Dell'Osso L.

Genetic study of bipolar disorder: taking seriously the problem of controls selection
pp. 246s-246s(1)
Authors: Chiaroni P.; Hantouche E.-G.; Azorin J.-M.

Structure of personality and depressive disorder
pp. 246s-246s(1)
Authors: Vertogradova O.P.; Bannikov G.S.; Konkov S.A.

Personality traits in mood disorders: association with polymorphisms of the dopamine D 3 receptor gene?
pp. 246s-246s(1)
Authors: Urmann A.; Willeit M.; Heiden A.; Scharfetter J.; Fuchs K.; Nilsson L.; Miller-Reiter E.; Gebhardt C.; Hornik K.; Sieghart W.; Kasper S.; Aschauer H.N.

A forensic case of dissociative identity disorder (DID) and the recently increased reports of DID in Japan
pp. 246s-247s(2)
Authors: Uchinuma Y.; Sekine Y.

The structure alteration of the depressive pathology in conditions of major social breakdown
pp. 247s-247s(1)
Authors: Tudose C.; Tudose F.

PTSD in ambulant road traffic accident victims: prevalence, predictors and a controlled study of the prophylactic value of psychological debriefing
pp. 247s-247s(1)
Authors: Conlon L.; Fahy T.J.

Posttraumatic stress disorders of Afghanistan combat veterans
pp. 247s-247s(1)
Authors: Sidorov P.; Lukmanov M.; Kalinin A.

Psychiatric disorders among POWs in Bosnia during 1992-1995
pp. 247s-248s(2)
Author: Licanin I.

Childhood trauma and their consequences in period of adolescence
pp. 248s-248s(1)
Author: Ljubomirovic N.

Care arrangements for PTSD patients
pp. 248s-248s(1)
Authors: Franciskovic T.; Moro L.

How does the trauma impact the PTSD
pp. 248s-248s(1)
Authors: Rocevic-Grzeta I.; Moro L.; Franciskovic T.; Pernar M.

Psychovegetative disturbances as a component of symptomatology in the victims of the chernobyl NNP disaster consequences
pp. 248s-248s(1)
Authors: Krjukov V.; Krasnov V.; Yurkin M.

Mirtazapine: an alternative treatment for depressed patients with poor compliance due to sexual dysfunction
pp. 248s-249s(2)
Authors: Koutouvidis N.; Pratikakis M.

Peculiarities of clinics and treatment of mental disorders in victims of the tchernobyl disaster
pp. 249s-249s(1)
Authors: Vlokh I.; Kryzhanivska L.; Kulyk B.

Structure of care in psychiatric hospital units 22 years after the German ''psychiatrie-enquete''
pp. 249s-249s(1)
Authors: Steinert T.; Gebhardt R.P.

Help requirements of the chronically mentally ill - a field study on regional planning
pp. 249s-249s(1)
Authors: Welte W.; Laengle G.

Psychiatric admissions in a general hospital -- a five year follow-up
pp. 249s-249s(1)
Authors: Ruiz I.; Figueira M.L.

Youth's mental health and development of community mental health care services in Ukraine
pp. 250s-250s(1)
Author: Godlevsky A.G.

Ecology of psychotherapy. A view from the provinces of Russia
pp. 250s-250s(1)
Author: Yudin I.

Abstract(s)
pp. 250s-250s(1)
Authors: Quisi Q.; Di Sacco M.

Various ''faces'' of the placebo-effect
pp. 250s-251s(2)
Authors: Lurina N.; Shustov D.; Hovrachyov A.; Borozdin A.; Shustova S.

Treatment of premenstrual dysphoric disorder with fluoxetine during the luteal phase
pp. 251s-251s(1)
Authors: Crnobaric C.; Jasovic-Gasic M.; Milovanovic S.; Miljevic C.

Psychopharmacological therapy and pregnancy - problems and recommendations
pp. 251s-251s(1)
Authors: Garlipp P.; Haltenhof H.; Machleidt W.

Who attends and who doesn't keep their appointments in the private psychiatric practice
pp. 251s-251s(1)
Authors: De las Cuevas C.; Garcia-Estrada A.

Countertransference in psychotherapy of young people with suicidal behaviour
pp. 251s-251s(1)
Author: Krsmanovic M.

The baby's gender actual planning as the couple's disharmony way of treatment
pp. 252s-252s(1)
Authors: Vassiltchenko G.; Zharkov Y.

Psychotherapy of the dying person: what we teach patients
pp. 252s-252s(1)
Authors: Le Quang D.; Le Quang Q.; Bekechi R.; Lang P.A.

Qualitative follow-up study of patients' view on their psychotherapy
pp. 252s-252s(1)
Author: Langagergaard A.

Musical hearing preferences of psychiatric in-patients
pp. 252s-252s(1)
Authors: Bertling R.; Harenbrock S.; Agelink M.

Who are those relatives of acutely admitted psychiatric patients who feel guilty?
pp. 252s-252s(1)
Authors: Windhaber J.; Wancata J.; Bankier B.; Amering M.; Katschnig H.

Work experience instead of occupational therapy -- evaluation of the Tuebingen model
pp. 253s-253s(1)
Authors: Laengle G.; Koester M.; Renner G.; Guenthner A.; Welte W.

Rhythmical changes of the cutaneous blood-flow under the condition of functional relaxation
pp. 253s-253s(1)
Authors: Buche R.; Hager D.; Muck-Weymann M.

Semiology as a scientific basis for the theory of medicine and psychiatry
pp. 253s-253s(1)
Author: Zorin N.A.

Abstract(s)
pp. 253s-253s(1)
Authors: Quisi Q.; Di Sacco M.

Heterogeneity of the ''possession states'': a case study from Pemba
pp. 254s-254s(1)
Author: Onchev G.

Two diagnostic approaches to the extrasensory healers' mental status
pp. 254s-254s(1)
Author: Karagodina O.G.

Number of older siblings in schizophrenia compared to neurosis: is there an interaction with urban birth and season of birth?
pp. 254s-254s(1)
Authors: McDonald C.; O'Callaghan E.; Keogh F.; Kinsella A.; Morris M.; Walsh D.

Citalopram infusion therapy of uni- and bipolar depression
pp. 254s-255s(2)
Authors: Kovacs G.; Kelemen E.

Abstract(s)
pp. 255s-255s(1)
Authors: Chneiweiss L.; Musa C.; Perrin E.; Albert E.

Gender and schizophrenia: clinical profiles
pp. 255s-255s(1)
Authors: Rodado M.J.; Rodado J.; Hernandez J.

Abstract(s)
pp. 255s-255s(1)
Authors: Laxenaire M.; Senninger J.L.

Olanzapine in haloperidol treatment failure
pp. 255s-256s(2)
Authors: Mraz K.; Alexandrescu L.; Klar B.; Uta D.; Kratky P.; Dossenbach M.

Clozapine dosage and WBC count correlation
pp. 256s-256s(1)
Authors: Todorovic M.; Aleksic S.; Stojanovic M.; Timotijevic I.

Personality disorders and depression -- clinical manifestations
pp. 257s-257s(1)
Author: Lecic-Tosevski D.

Atypical versus nonatypical depression in 203 private practice outpatients
pp. 257s-257s(1)
Author: Benazzi F.

Somatic symptoms in depression
pp. 257s-257s(1)
Authors: Akbiyik D.I.; Onder M.E.

Psychopathology of dysthymia
pp. 258s-258s(1)
Authors: Serretti A.; Jori M.C.; Bellino S.

Perceptions of support and coping with chronic fatigue syndrome
pp. 258s-258s(1)
Authors: Ax S.; Gregg V.H.; Jones D.

The nuclear affects in anxious depression
pp. 258s-258s(1)
Authors: Veltischev D.; Gurevich J.; Seravina O.

Somatic comorbidity and depression in the hospital setting
pp. 258s-258s(1)
Authors: Ruiz M.R.; Rodriguez-Rosado A.; Andreu J.M.P.

Improvement of neurocardial vagal dysfunction after successful antidepressive treatment with electroconvulsive therapy (ECT)
pp. 259s-259s(1)
Authors: Agelink M.W.; Lemmer W.; Malessa R.; Zeit T.; Klieser E.

Adrenaline and imidazoline drug-induced platelet aggregation in patients with major depression
pp. 259s-259s(1)
Authors: Jaquet P.E.; Ferrer-Alcon M.; Walzer C.; Garcia-Sevilla J.A.; Guimon J.

Cholesterol and serotonergic control of prolactin secretion in depressed and suicidal patients
pp. 259s-260s(2)
Authors: Sarchiapone M.; Roy A.; Camardese G.; Casa S.D.; Satta M.A.; De Risio S.

Successful pharmacotherapy of cotard syndrome with reduction of D₂ receptors in basal ganglia
pp. 260s-260s(1)
Authors: De Risio S.; Sarchiapone M.; Camardese G.; Calvosa F.; Buonanno A.; Barbarino E.

Predictive power of Beck's depression inventory in the general population
pp. 260s-260s(1)
Authors: Lasa L.; Ayuso-Mateos J.L.; Vazquez-Barquero J.L.

Health economics of antidepressants: a methodological review
pp. 260s-260s(1)
Authors: Hylan T.R.; Buesching D.P.; Tollefson G.D.

Does St. John's wort have an effect on autonomic responses of cutaneous circulation?
pp. 260s-261s(2)
Authors: Muck-Weymann M.; Mosler T.; Buche R.; Rechlin T.

Pharmacotherapy of depression and chronic pain
pp. 261s-261s(1)
Authors: Munjiza M.; Popovic-Deusic S.; Nikolic M.; Ljubomirovic N.; Velickovic N.

Efficacy and tolerance of venlafaxine in hospitalized and ambulatory patients
pp. 261s-261s(1)
Authors: Kontis K.; Zissis N.P.; Bouka E.; Vidalis A.; Pappas E.; Polyzoidis L.; Kalogeropoulos A.

Pridictors of response to antidepressant drug therapy and their significance for the duration of treatment
pp. 261s-261s(1)
Authors: Laakmann G.; Schule C.; Baghai T.; Kraus J.

Cortisol-, growth hormone-, prolactin-, and TSH-response to combined pituitary stimulation test in depressive patients and healthy controls
pp. 262s-262s(1)
Authors: Schule C.; Laakmann G.; Baghai T.; Kraus J.

Antidepressant use in primary care in the United Kingdom: a longitudinal study of prescribing patterns
pp. 262s-262s(1)
Authors: Donoghue J.M.; Hylan T.

Patterns of antidepressant use and their relation to clinical global impression scores
pp. 262s-262s(1)
Authors: Hylan T.R.; Meneades L.; Crown W.H.; Sacristan J.; Gilaberte I.; Montejo A.L.

SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis
pp. 262s-263s(2)
Authors: Hylan T.R.; Meneades L.; Crown W.H.; Melfi C.A.; Croghan T.W.; Buesching D.P.

The cost-effectiveness of Ixel(R), a new SNRI, in comparison with a panel of TCAs and SSRIs, in the treatment of depression
pp. 263s-263s(1)
Authors: Berdeaux G.; Dardennes R.; Lafuma A.; Fagnani F.

Citalopram treats major depression in the elderly, with fewer side effects than amitriptyline
pp. 263s-263s(1)
Authors: Kyle C.J.; Petersen H.E.H.

Citalopram is effective and well tolerated in patients with major depressive disorder
pp. 263s-264s(2)
Authors: Feighner J.; Overo K.F.

Citalopram infusion is a useful alternative to tablets in hospitalised patients with depression
pp. 264s-264s(1)
Authors: Baumann P.; Nil R.

Benefits of citalopram vs viloxazine, both given as an intravenous-to-oral regimen for severe depression
pp. 264s-264s(1)
Authors: Bouchard J.M.; Nil R.

Tolerability of 15 vs 30 mg initial doses of mirtazapine: a randomized, double-blind study
pp. 264s-264s(1)
Authors: Helsdingen J.T.H.; Zivkov M.

Mirtazapine vs fluoxetine: efficacy on symptoms associated with depression
pp. 265s-265s(1)
Authors: Kremer C.M.E.; Zivkov M.; Helsdingen J.T.H.

A naturalistic study of mirtazapine in the German psychiatric practice
pp. 265s-265s(1)
Authors: Pattenier A.-M.; Helsdingen J.T.

Economic impact of using mirtazapine
pp. 265s-265s(1)
Authors: Brown M.C.J.; Guest J.F.; van Loon J.; Bruin R.

The clinical course and resolution of mirtazapine-induced edema
pp. 265s-266s(2)
Authors: Lahdelma L.; Bruin R.

The use of mirtazapine in primary care
pp. 266s-266s(1)
Authors: Kreuzenbeck H.-J.; Helsdingen J.T.

In vitro metabolism of S-(+)- and R-(-)-enantiomers of mirtazapine
pp. 266s-266s(1)
Authors: Delbressine L.P.C.; Vos R.M.E.; Pinder R.

The influence of mirtazapine on anterior pituitary hormone secretion in healthy subjects
pp. 266s-266s(1)
Authors: Laakmann G.; Schule C.; Baghai T.; Kraus J.

Economic impact of using mirtazapine in the management of moderate and severe depression in Austria
pp. 266s-267s(2)
Authors: Brown M.C.J.; Nimmerrichter A.A.; Guest J.F.

Pregnancy during use of mirtazapine
pp. 267s-267s(1)
Authors: Simhandl C.; Zoghlami A.; Pinder R.

Effects of milnacipran and venlafaxine on extracellular levels of 5-HT and noradrenaline in Guinea pig hypothalamus
pp. 267s-267s(1)
Authors: Moret C.; Marien M.

Abstract(s)
pp. 267s-268s(2)
Authors: Dovzhenko T.; Krasnow V.; Maichuk E.; Gabrieljan A.

Venlafaxine in elderly depressed patients. A multicenter study
pp. 268s-268s(1)
Authors: Ayuso J.L.; Giner J.; Ballus C.; Carrasco J.L.; Moreno A.

Optimal length of continuation therapy: a prospective assessment during fluoxetine long-term treatment of major depressive disorder
pp. 268s-268s(1)
Authors: Michelson D.; Wilson M.; Sundell K.; Beasley C.

Adverse event profiles associated with long-term fluoxetine treatment
pp. 268s-268s(1)
Authors: Michelson D.; Tamura R.; Sundell K.; Beasley C.

Changes in insomnia during treatment of depression: analysis of fluoxetine double-blind, placebo-controlled trials
pp. 268s-269s(2)
Authors: Romano S.J.; Tepner R.G.; Basson B.R.

Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in patients with low and high baseline insomnia
pp. 269s-269s(1)
Authors: Fava M.; Rosenbaum J.F.; Hoog S.L.; Tepner R.G.; Kopp J.B.; Sayler M.

Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in patients with high and low baseline anxiety
pp. 269s-269s(1)
Authors: Fava M.; Rosenbaum J.F.; Hoog S.L.; Tepner R.G.; Kopp J.B.; Sayler M.

Combined moclobemid, promazine administration--a safety treatment in elderly depressive agitation
pp. 269s-269s(1)
Author: Marinkovic D.

Peculiarities of depressive disorders in patients with chronic hepatitis of different aetiology
pp. 270s-270s(1)
Authors: Podrezova L.A.; Babkin D.I.; Tsodikov G.V.

Dopamine agonist treatment of chronic depression
pp. 270s-270s(1)
Authors: Tsukarzi E.; Mosolov S.; Missionznik E.; Uzbekov M.; Sharov A.

Venlafaxine: a useful addition in rational antidepressive treatment
pp. 270s-270s(1)
Authors: Agelink M.W.; Lemmer W.; Ullrich H.; Zeit T.; Klieser E.

Effects of once-daily extended release (XR) venlafaxine on anxiety in patients with major depression
pp. 270s-271s(2)
Authors: Rudolph R.L.; Entsuah A.R.

Comparative efficacy of once-daily venlafaxine XR and fluoxetine in depressed patients with concomitant anxiety
pp. 271s-271s(1)
Authors: Hackett D.; Desmet A.; White C.; Salinas E.

Effectiveness of sulpiride vs. mianserine in treatment of late-life psychotic depression
pp. 271s-271s(1)
Author: Stankovic Z.

Semiotic of dysthymia in general somatic practice in West Siberia
pp. 271s-271s(1)
Authors: Kornetov N.A.; Poleshuk M.V.

The structure of perfectionism as the personal factor in depression
pp. 271s-272s(2)
Authors: Garanian N.; Kholmogorowa A.; Judeeva T.

Repetitive transcranial magnetic stimulation (rTMS) in major depression -- short-term antidepressive effects
pp. 272s-272s(1)
Authors: Weber B.; Schwarzenau K.; Eckert J.; Gille B.; Fey P.; Fritze J.; Maurer K.

Complex treatment of resistant depression
pp. 272s-272s(1)
Authors: Gorobetz L.; Krasnov V.; Emelyanova I.

Correlation between symptomatology and personality traits in depressive patients
pp. 272s-272s(1)
Author: Marin A.

The integration of cognitive and dynamic approaches in the psychotherapy of emotional disorders
pp. 272s-272s(1)
Authors: Kholmogorowa A.; Garanian N.

Family dysfunction and depression among adolescents (cross-cultural study)
pp. 273s-273s(1)
Authors: Kim L.; Ermolina L.

Abstract(s)
pp. 273s-273s(1)
Authors: Kholmogorowa A.; Wolikowa S.

Elderly's agitation and aggressiveness in primary health care
pp. 273s-273s(1)
Authors: Leger J.M.; Gerard D.

Prevalence and course of psychiatric disorders among nursing home admissions
pp. 273s-273s(1)
Authors: Wancata J.; Benda N.; Hajji M.

Geriatric psychiatry in Denmark, a description of trends in admission pattern and service provision
pp. 274s-274s(1)
Authors: Lien K.; Sorensen L.

Somatic comorbidity in patients with dementia: Alzheimer disease versus mixed dementia and vascular dementia
pp. 274s-274s(1)
Authors: de Mendonca Lima C.A.; Sanchez S.L.; Tschan I.; Simeone I.

Validation of the standardised mini mental state examination
pp. 274s-274s(1)
Authors: Sorensen L.; Foldspang A.; Gulmann N.C.; Nielsen S.J.; Mehlsen M.; Munk-Jorgensen P.

Use of critical flicker fusion threshold in patients with alzheimer's disease
pp. 274s-275s(2)
Author: Curran S.

Effectiveness of tiapride in behavioral disorders of demented elderly
pp. 275s-275s(1)
Authors: Allain H.; Soubrane C.; Turjanski S.; Bonhomme D.

Syndrome of depression during alzheimer's disease and therapeutic effects
pp. 275s-275s(1)
Authors: Munjiza M.; Nikolic M.; Velickovic M.

Management of suicidality in old age: results from a representative survey in primary care
pp. 276s-276s(1)
Authors: Stoppe G.; Sandholzer H.; Huppertz C.; Duwe H.; Staedt J.

Diurnal sleep impairs cognitive performances in elderly: physiopathologic hypothesis
pp. 276s-276s(1)
Authors: Tatarelli R.; Curti E.; Del Nero P.; Gori M.C.; Girardi P.

Diagnosis of depression in the elderly in the german primary care situation
pp. 276s-277s(2)
Authors: Stoppe G.; Sandholzer H.; Huppertz C.; Duwe H.; Staedt J.

Psychopathology and five-year suicide risk in major depression
pp. 277s-277s(1)
Authors: Schneider B.; Philipp M.

Schizophrenic inpatients with suicidal thoughts
pp. 277s-277s(1)
Authors: Kontaxakis V.; Havaki-Kontaxaki B.; Margariti M.; Stamouli S.; Kollias K.; Feretopoulos G.; Christodoulou G.N.

Risk factors and profiles in attempted suicide
pp. 277s-277s(1)
Authors: Irurita J.; Irurita M.; Betancor P.; Saavedra P.; Los Santos R.

A comparison of suicide between Denmark and China
pp. 278s-278s(1)
Authors: Qin P.; Mortensen P.B.

A primary prevention project of suicidal risk in relation to the loss of working activity
pp. 278s-278s(1)
Author: Mattia M.

Abstract(s)
pp. 278s-278s(1)
Authors: Chastang F.; Dupont I.; Rioux P.; Kovess V.; Zarifian E.

Abstract(s)
pp. 278s-279s(2)
Authors: Chastang F.; Dupont I.; Rioux P.; Kovess V.; Zarifian E.

Pharmacologic prevention of suicide
pp. 279s-279s(1)
Author: Gaszner P.

Suicide in prison -- is the risk really highest in the first period of custody? Prison suicide in Austria 1975-96
pp. 279s-279s(1)
Authors: Frottier P.; Fruhwald S.; Grunhut C.; Aigner M.; Eher R.; Gutierrez-Lobos K.

Parasuicide, anhedonia and depression
pp. 279s-279s(1)
Authors: Loas G.; Perot J.M.; Chignague J.F.; Trespalacios H.; Delahousse J.

Decreasing suicide mortality in Hungary: which are the main causes?
pp. 279s-279s(1)
Authors: Rihmer Z.; Furedi J.; Pestality P.; Szabo P.

Abstract(s)
pp. 280s-280s(1)
Authors: Quisi Q.; Di Sacco M.; Cardoso C.

Symptomatology profile of combat veterans with PTSD
pp. 280s-280s(1)
Authors: Samardzic R.; Spiric Z.; Preradovic M.; Zujovic T.; Kuljic B.

Abstract(s)
pp. 280s-280s(1)
Authors: Siurkute A.; Stigiene A.

Absence of insomnia in panic disorder: is it related to a predisposition to affective illness?
pp. 280s-280s(1)
Authors: Arriaga F.; Cavaglia F.; Matos-Pires A.; Abreu M.; Lara E.

Comparison of male and female patients with agoraphobia
pp. 281s-281s(1)
Authors: Starcevic V.; Djordjevic A.; Latas M.; Bogojevic G.

Disabilities in panic disorder with comorbid phobias
pp. 281s-281s(1)
Authors: Maierhofer D.; Holzinger A.; Sachs G.; Berger P.; Windhaber J.; Amering M.; Bankier B.; Dantendorfer K.; Katschnig H.

Impaired conditional discrimination in panic disorder patients
pp. 281s-281s(1)
Authors: Dantendorfer K.; Maierhofer D.; Katschnig H.

Temperament dimensions and long term incapacity in panic disorder patients
pp. 282s-282s(1)
Authors: Figueira M.L.; da Silva M.J.F.; e Silva R.M.; Ramos V.; Albuquerque R.

Interpersonal problems and psychosocial disabilities in panic disorder
pp. 282s-282s(1)
Authors: Sachs G.; Berger P.; Amering M.; Holzinger A.; Maierhofer D.; Bankier B.; Windhaber H.; Katschnig H.

Catastrophic cognitions and avoidance behavior in panic disorder patients
pp. 282s-282s(1)
Authors: Windhaber J.; Berger P.; Amering M.; Maierhofer D.; Sachs G.; Bankier B.; Holzinger A.; Dantendorfer K.; Katschnig H.

Panic disorder and cigarette smoking behaviour
pp. 282s-283s(2)
Authors: Amering M.; Bankier B.; Berger P.; Griengl H.; Windhaber J.; Katschnig H.

Cognitions and disabilities in panic disorder
pp. 283s-283s(1)
Authors: Bankier B.; Berger P.; Amering M.; Sachs G.; Holzinger A.; Maierhofer D.; Katsching H.

Panic disorder with agoraphobia and marital and sexual functionality
pp. 283s-283s(1)
Authors: Dimitrijevic B.; Dimitrijevic I.; Pejovic M.

The application of the panic and agoraphobia scale (P & A) in clinical trials
pp. 283s-283s(1)
Authors: Bandelow B.; Broocks A.; Ruther E.

Citalopram is as effective as clomipramine for treating panic disorder, and is better tolerated
pp. 284s-284s(1)
Authors: Lepola U.M.; Wade A.G.; Pedersen V.

Long-term treatment in panic disorder: randomization of acute fluoxetine responders to continued treatment with fluoxetine or placebo
pp. 284s-284s(1)
Authors: Michelson D.; Lydiard R.B.; Pollack M.; Tamura R.; Tepner R.; Tollefson G.

Fluoxetine treatment of panic disorder: a randomized, placebo-controlled, multi-center trial
pp. 284s-284s(1)
Authors: Michelson D.; Lydiard R.B.; Pollack M.H.; Tamura R.; Tepner R.; Tollefson G.

¹²³I-Iomazenil spet reveals increased prefrontal benzodiazepine receptor density in panic disorder
pp. 285s-285s(1)
Authors: Stoppe G.; Brandt C.; Meller J.; Keweloh L.; Hoschel K.; Staedt J.

Prolactin response to TRH in patients with panic disorder
pp. 285s-285s(1)
Authors: Tukel R.; Kora K.; Hekim N.; Oguz H.; Alagol F.

A cross-sectional survey of sexual dysfunction in patients taking antipsychotic medication
pp. 285s-285s(1)
Authors: Smith S.; Mostyn P.; Vernals S.; O'Keane V.; Murray R.

Testesterone & pituitary hormones in sexual dysfunction
pp. 285s-286s(2)
Authors: El-hinnawey A.; Shaban H.; Shaban M.

A sexual behaviour correction of young physically handicapped men
pp. 286s-286s(1)
Author: Taktarov V.G.

Peculiarities of sexual dysfunction in men of declining years
pp. 286s-286s(1)
Authors: Yagubov M.; Kibrik N.

Aging pecularities of development of the sexual disfunctions
pp. 286s-286s(1)
Author: Kibrik N.D.

Complex therapy in sex reassignment process
pp. 287s-287s(1)
Author: Vasilenko L.M.

Clinical presentation and therapy of sexual somatization disorders in males
pp. 287s-287s(1)
Author: Kan I.

Sexual angedonia in women
pp. 287s-287s(1)
Authors: Airiants I.; Kibrik N.

Different factors influencing the decision to change the gender
pp. 287s-288s(2)
Author: Dolnykova A.A.

Predictors of psychosocial functioning in affective disorders and schizophrenia
pp. 289s-289s(1)
Authors: Schneider B.; Miketta-Ebel S.; Philipp M.

Self- and other-directed aggressive behaviour and early course of illness in schizophrenia
pp. 289s-289s(1)
Authors: Steinert T.; Wiebe C.; Gebhardt R.P.

Relationship status in first onset schizophrenia
pp. 289s-290s(2)
Authors: Hutchinson G.; Burnett R.; Mallet R.; Bhugra D.; Leff J.

Schizophrenia and rehabilitation
pp. 290s-290s(1)
Authors: Barisic-Rojnic J.; Leposavic L.; Nikolic-Baltoski G.

Verbal memory impairment in schizophrenia
pp. 290s-290s(1)
Authors: Nikolic-Balkoski G.; Leposavic L.; Jasovic-Gasic M.; Barisic-Rojnic J.

Regional differences in schizophrenia: incidence, gender, age and diagnostic delay
pp. 290s-290s(1)
Authors: Schelin E.M.; Munk-Jorgensen P.; Gerlach J.

The course of patients admitted with the diagnosis of schizophrenia before the age of 15 years
pp. 290s-291s(2)
Authors: Ramsing P.; Thomsen P.H.

Quality of life of patients with chronic course schizophrenia
pp. 291s-291s(1)
Author: Bohuta C.

Quality of life in schizophrenia related to subjective distress from symptoms and medication
pp. 291s-291s(1)
Authors: Knudstorp T.; Gerlach J.

Self-esteem, self-efficacy, and subjective quality of life in schizophrenic patients
pp. 291s-291s(1)
Authors: Franz M.; Meyer T.; Hanewald B.; Runzheimer P.; Gallhofer B.

Abstract(s)
pp. 291s-291s(1)
Authors: Planas P.; Gonzalez J.; Umm M.; Lang P.A.

Strategies for enhancing self-esteem and social integration of patients with schizophrenia
pp. 292s-292s(1)
Author: Haghighat R.